Discloses a pharmaceutical composition comprising: { 1 S-[1 0, 20, 313 (1 S*,2R*),513]} -3-(7 -{ [2-(3,4-difluorophenyl)cyclopropyl]amino} -5-(propylthio )-3H-1 ,2,3-triazolo[4,5-d]pyrimidin-3-yl)-5-(2-hydroxyethoxy)cyclopentane-1,2-diol, a filler of the general structure (I) in the drawing which is a mixture of mannitol and dibasic calcium phosphate dehydrate, a binder which is hydroxypropyl cellulose, disintegrant which is sodium starch glycollate and one or more lubricants. The pharmaceutical composition disclosed has a therapeutic application in the treatment of thrombosis associated conditions.
